Sanofi Anticipates a 30% Cost Reduction With Veeva Training System
At the 2025 Veeva R&D and Quality Summit, Sanofi unveiled a transformative approach to study training within clinical operations,...
HeartFlow Plaque Analysis Impacts Coronary Artery Disease Management
Heartflow, Inc. announced positive data from the DECIDE Registry, demonstrating that their AI-powered Heartflow Plaque Analysis led to treatment...
Five Abstracts on SPRINT® PNS at ASPN 2025
SPR Therapeutics presented data at the American Society of Pain & Neuroscience (ASPN) Annual Conference demonstrating the effectiveness of...
Actuate’s Ewing Sarcoma Trial Shows Promise in Pediatric Sarcomas
Actuate Therapeutics has completed Phase 1 of its elraglusib study in pediatric patients with refractory cancers, observing promising results...
Lisata and WarpNine Announce ILSTA Trial Completion & Data
Lisata Therapeutics and WARPNINE Incorporated completed patient enrollment in their Phase 1b/2a iLSTA trial in Australia. The trial evaluates...
Keros Doses First Patient in Phase 3 Trial of Elritercept
Keros Therapeutics initiated Phase 3 trials for elritercept, a treatment for transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS)....
Gets FDA Orphan Drug Designation for AML Treatment
ImCheck Therapeutics’ lead candidate, ICT01, has received FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (AML)....
Strong Clinical Trial Results for Urcosimod
OKYO Pharma’s Phase 2 trial of urcosimod for neuropathic corneal pain (NCP) yielded positive top-line results. The trial involved...
CUE-101 & Pembro Show Promising 50% Response in HPV+ Head & Neck Cancer Trial
Cue Biopharma announced positive clinical updates for CUE-101, its lead drug candidate for recurrent/metastatic head and neck squamous cell...
Zervimesine Shows Promise in Dementia with Lewy Bodies
Cognition Therapeutics announced positive Phase 2 results for zervimesine in treating dementia with Lewy bodies (DLB) at the Alzheimer’s...